

Alzinova publishes annual report for 2024

Alzinova AB (publ) (“Alzinova” or the “Company”) hereby publishes its annual report for the financial year 2024. The annual report, which is attached to the press release, can also be downloaded from the Company’s website, <https://www.alzinova.com/investors/financial-reports/>.

For more information, please contact:

Tord Labuda, CEO
E-mail: info@alzinova.com

Erik Kullgren, CFO
E-mail: info@alzinova.com

About Alzinova AB

Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented A β CC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com